Brief: Hookipa Pharma Announces First Person Dosed In Phase 1B Clinical Trial Of Hb-500 For The Treatment Of HIV
01/07/2024 21:33
July 1 (Reuters) - HOOKIPA Pharma Inc HOOK.O :
* HOOKIPA PHARMA ANNOUNCES FIRST PERSON DOSED IN PHASE 1B
CLINICAL
TRIAL OF HB-500 FOR THE TREATMENT OF HIV
* HOOKIPA PHARMA INC - HOOKIPA ACHIEVES A $5 MILLION
NON-DILUTIVE
MILESTONE PAYMENT UNDER ITS COLLABORATION AND LICENSE AGREEMENT
WITH GILEAD
* HOOKIPA PHARMA INC - UNDER COLLABORATION AGREEMENT,
HOOKIPA IS
RESPONSIBLE FOR ADVANCING HIV PROGRAM THROUGH COMPLETION OF A
PHASE 1B CLINICAL TRIAL
Source text for Eikon: ID:nGNXDstWd
Further company coverage: HOOK.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hookipa Pharma
See all newsBrief: Hookipa Pharma Announces Sale Of Oncology Assets To Neotrail Therapeutics
Brief: Hookipa Pharma Announces Intention To Voluntarily Delist And Deregister Its Common Stock
Hookipa Pharma Inc Expected To Post A Loss Of $1.04 A Share: Earnings Preview
Brief: Poolbeg Pharma Says Hookipa Terminated Discussions On Proposed Merger
HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)